4BIO Capital Announces Strategic Partnership with Harbor Capital Advisors

SparingVision announces strategic collaboration with Intellia Therapeutics

4BIO Capital Co-leads $10 Million Seed Financing in Code Biotherapeutics

SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics

4BIO Joins Investor Syndicate in CARISMA Therapeutics’ Second Closing of $59 Million Series B Round

4BIO Capital’s review of AAV gene therapy clinical trials published in Nature Reviews Drug Discovery